Olean Times Herald

- Topline results expected by end of Q2 2025 – - Phase 1 enrolled 22 patients to examine the safety profile in patients suffering from primary osteoar...

Cytonics Seeks$24 millionto pursue FDA Phase 2 Clinical Study of CYT-108, the Company's Novel Therapy for Osteoarthritis JUPITER, Fla. , March 25, 202...

– No adverse events reported; CYT-108 progressing as a potential disease-modifying therapy for osteoarthritis – JUPITER, Fla. , Jan. 21, 2025 /PRNewsw...